Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Income (2016 - 2026)

Amphastar Pharmaceuticals has reported Operating Income over the past 13 years, most recently at -$78.8 million for Q4 2025.

  • For Q4 2025, Operating Income fell 274.63% year-over-year to -$78.8 million; the TTM value through Dec 2025 reached $26.0 million, down 87.36%, while the annual FY2025 figure was $26.0 million, 87.36% down from the prior year.
  • Operating Income for Q4 2025 was -$78.8 million at Amphastar Pharmaceuticals, down from $25.3 million in the prior quarter.
  • Over five years, Operating Income peaked at $72.7 million in Q3 2023 and troughed at -$78.8 million in Q4 2025.
  • A 5-year average of $30.3 million and a median of $35.2 million in 2023 define the central range for Operating Income.
  • Biggest five-year swings in Operating Income: surged 742.38% in 2021 and later tumbled 274.63% in 2025.
  • Year by year, Operating Income stood at $24.3 million in 2021, then surged by 56.0% to $37.8 million in 2022, then soared by 42.68% to $54.0 million in 2023, then fell by 16.37% to $45.1 million in 2024, then tumbled by 274.63% to -$78.8 million in 2025.
  • Business Quant data shows Operating Income for AMPH at -$78.8 million in Q4 2025, $25.3 million in Q3 2025, and $42.2 million in Q2 2025.